Page 10 - Flipbook
P. 10

Abstracts – Oral session

           4503            M. Galsky et al.            Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in

                                                      patients with muscle- invasive bladder cancer (MIBC): HCRN GU 16-257

           4504              A. Balar et al.           Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent

                                                      hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive

                                                      urothelial cancer of the bladder (MIBC): A multicenter phase 2 trial

           4505           X. del Muro et al.           Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy (RT) in

                                                      patients (pts) with localized muscle invasive bladder cancer (MIBC) treated with a selective

                                                      bladder preservation approach: IMMUNOPRESERVE-SOGUG trial

   Radiation Oncology
   5   6   7   8   9   10   11   12   13   14   15